Aura Biosciences, Inc. (AURA)

• $7.10

  $7.33

  $7.10
  

  0.0%

  Downside

  Day's Volatility :3.14%

  Upside

  3.14%

  
• $5.99

  $13.50

  $7.10
  

  15.63%

  Downside

  52 Weeks Volatility :55.63%

  Upside

  47.41%

  

Returns

What analysts predicted

Upside of 178.87%

• Matrix Capital Management Company, LLC

  14.05%

• Eventide Asset Management, LLC

  11.78%

• Adage Capital Partners Gp LLC

  8.58%

• Medicxi Ventures Management (Jersey) Ltd

  6.17%

• Nantahala Capital Management, LLC

  5.37%

• Citadel Advisors Llc

  5.04%

• Aura Biosciences, Inc. Earnings

  Aura Biosciences, Inc.’s price-to-earnings ratio stands at None

  Read More

at aura biosciences, we are developing a new class of therapies to target and destroy cancer cells selectively, while leaving surrounding tissue unharmed – an approach we call molecular surgery. by safely eliminating cancer locally, we can treat early and transform the lives of people with a wide range of cancers that are poorly managed today. our lead program in ocular melanoma (om), also known as choroidal or uveal melanoma, is designed to remove cancer cells in the back of the eye as a first-line therapy, while allowing for the potential of preserving patients’ vision. the goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. development of a first-in-class, non-radioactive treatment option to selectively destroy cancer cells would create the possibility to transform the treatment of this and other cancers where the disease can be detected early. by enabling physicians to treat cancer mo